$CDXC
ChromaDex Corp. Stock $cdxc

$cdxc Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035591 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$25.58M	$22.74M
YoY Change	31.21%	11.89%
Cost Of Revenue	$9.340M	$9.046M
YoY Change	24.1%	13.54%
Gross Profit	$16.24M	$13.69M
YoY Change	35.68%	10.82%
Gross Profit Margin	63.49%	60.22%
Selling, General & Admin	$13.35M	$12.63M
YoY Change	12.4%	-5.07%
% of Gross Profit	82.19%	92.26%
Research & Development	$1.290M	$1.316M
YoY Change	3.95%	-3.59%
% of Gross Profit	7.94%	9.61%
Depreciation & Amortization	$202.0K	$207.0K
YoY Change	-25.19%	-23.62%
% of Gross Profit	1.24%	1.51%
Operating Expenses	$14.64M	$13.95M
YoY Change	11.6%	-4.93%
Operating Profit	$1.602M	-$256.0K
YoY Change	-239.67%	-88.95%
Interest Expense	$276.0K	$241.0K
YoY Change	45.26%	92.8%
% of Operating Profit	17.23%
Other Income/Expense, Net
YoY Change
Pretax Income	$1.878M	-$15.00K
YoY Change	-295.63%	-99.32%
Income Tax
% Of Pretax Income
Net Earnings	$1.878M	-$15.00K
YoY Change	-295.83%	-99.32%
Net Earnings / Revenue	7.34%	-0.07%
Basic Earnings Per Share	$0.02	$0.00
Diluted Earnings Per Share	$0.02	$0.00
COMMON SHARES
Basic Shares Outstanding	75.93M shares	75.54M shares
Diluted Shares Outstanding	77.77M shares	75.56M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.25M	$27.73M
YoY Change	21.13%	5.63%
Cash & Equivalents	$32.20M	$27.70M
Short-Term Investments
Other Short-Term Assets	$2.248M	$2.240M
YoY Change	-3.52%	9.97%
Inventory	$10.54M	$11.51M
Prepaid Expenses
Receivables	$7.096M	$7.818M
Other Receivables	$2.000M	$3.500M
Total Short-Term Assets	$52.13M	$49.30M
YoY Change	10.5%	6.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.617M	$3.904M
YoY Change	-31.75%	-31.27%
Goodwill
YoY Change
Intangibles	$397.0K	$435.0K
YoY Change	-28.08%	-26.4%
Long-Term Investments
YoY Change
Other Assets	$374.0K	$394.0K
YoY Change	-17.62%	-23.94%
Total Long-Term Assets	$4.388M	$4.733M
YoY Change	-30.37%	-30.28%
TOTAL ASSETS
Total Short-Term Assets	$52.13M	$49.30M
Total Long-Term Assets	$4.388M	$4.733M
Total Assets	$56.52M	$54.04M
YoY Change	5.68%	1.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.903M	$8.105M
YoY Change	-24.95%	-19.2%
Accrued Expenses	$9.592M	$8.621M
YoY Change	4.34%	6.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.00K	$12.00K
YoY Change	20.0%	20.0%
Total Short-Term Liabilities	$17.70M	$17.87M
YoY Change	-8.97%	-6.26%
LONG-TERM LIABILITIES
Long-Term Debt	$2.000K	$6.000K
YoY Change	-80.0%	-64.71%
Other Long-Term Liabilities	$4.452M	$5.444M
YoY Change	-33.75%	-21.59%
Total Long-Term Liabilities	$4.454M	$5.450M
YoY Change	-33.82%	-21.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.70M	$17.87M
Total Long-Term Liabilities	$4.454M	$5.450M
Total Liabilities	$22.15M	$23.32M
YoY Change	-15.37%	-10.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$189.1M	-$191.0M
YoY Change	-0.78%	0.71%
Common Stock	$76.00K	$75.00K
YoY Change	1.33%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.37M	$30.72M
YoY Change
Total Liabilities & Shareholders Equity	$56.52M	$54.04M
YoY Change	5.68%	1.62%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$1.878M	-$15.00K
YoY Change	-295.83%	-99.32%
Depreciation, Depletion And Amortization	$202.0K	$207.0K
YoY Change	-25.19%	-23.62%
Cash From Operating Activities	$3.495M	-$264.0K
YoY Change	773.75%	-108.05%
INVESTING ACTIVITIES
Capital Expenditures	$41.00K	$12.00K
YoY Change	36.67%	20.0%
Acquisitions
YoY Change
Other Investing Activities	$20.00K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$21.00K	-$12.00K
YoY Change	5.0%	140.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.039M	596.0K
YoY Change		-6060.0%
NET CHANGE
Cash From Operating Activities	3.495M	-264.0K
Cash From Investing Activities	-21.00K	-12.00K
Cash From Financing Activities	1.039M	596.0K
Net Change In Cash	4.513M	320.0K
YoY Change	1087.63%	-90.2%
FREE CASH FLOW
Cash From Operating Activities	$3.495M	-$264.0K
Capital Expenditures	$41.00K	$12.00K
Free Cash Flow	$3.454M	-$276.0K
YoY Change	833.51%	-108.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75559000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74967000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75394000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75559000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74981000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74981000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74882000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	598000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1185000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-15000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	30718000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28017000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2191000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	27150000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28456000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74967000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75394000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75394000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74882000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74882000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	784000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	774000	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	784000	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	774000	shares
	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	167000	shares
CY2024Q2	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	167000	shares
CY2023Q2	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	181000	shares
	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	182000	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
CY2024Q2	us-gaap	Revenues Revenues	22739000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	9046000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	13693000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6969000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1316000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5664000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	13949000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-256000	usd
CY2023Q2	us-gaap	Revenues Revenues	20323000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	7967000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	12356000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6009000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1365000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7298000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	14672000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2316000	usd
	us-gaap	Revenues Revenues	44892000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	17743000	usd
	us-gaap	Gross Profit GrossProfit	27149000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13709000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3411000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11016000	usd
	us-gaap	Operating Expenses OperatingExpenses	28136000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-987000	usd
	us-gaap	Revenues Revenues	42879000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	17005000	usd
	us-gaap	Gross Profit GrossProfit	25874000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13883000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2558000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13717000	usd
	us-gaap	Operating Expenses OperatingExpenses	30158000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4284000	usd
CY2024Q2	us-gaap	Revenues Revenues	22739000	usd
CY2023Q2	us-gaap	Revenues Revenues	20323000	usd
	us-gaap	Revenues Revenues	44892000	usd
	us-gaap	Revenues Revenues	42879000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5123000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5962000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2890000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3537000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2986000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4478000	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	512000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	548000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	11511000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	14525000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2100000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2400000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3100000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3300000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	230000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	450000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	461000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	97000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	59000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	205000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	112000	usd
CY2024Q2	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	316000	usd
CY2023Q2	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	289000	usd
	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	655000	usd
	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	573000	usd
CY2024Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	320000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	293000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	663000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	581000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	437000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1135000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	901000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	491000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	358000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	30000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3352000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	246000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3106000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	973000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2133000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.742
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.044
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q2	us-gaap	Share Price SharePrice	2.73
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1185000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1324000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2169000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2597000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5000000.0	usd
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	9800000	usd
CY2019Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	1600000	usd
CY2022Q3	cdcx	Other Income Net Employee Retention Credit Cares Act OtherIncomeNetEmployeeRetentionCreditCARESAct	2100000	usd
CY2023	cdcx	Proceeds From Employee Retention Tax Credit Cares Act ProceedsFromEmployeeRetentionTaxCreditCARESAct	900000	usd
CY2022	cdcx	Proceeds From Employee Retention Tax Credit Cares Act ProceedsFromEmployeeRetentionTaxCreditCARESAct	600000	usd
CY2024Q2	cdcx	Prepaid Expenses And Other Current Assets Employee Retention Credit Cares Act PrepaidExpensesAndOtherCurrentAssetsEmployeeRetentionCreditCARESAct	900000	usd
CY2024Q2	cdcx	Accrued Expenses Employee Retention Credit Cares Act AccruedExpensesEmployeeRetentionCreditCARESAct	100000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-035591-index-headers.html	Edgar Link	pending
0001628280-24-035591-index.html	Edgar Link	pending
0001628280-24-035591.txt	Edgar Link	pending
0001628280-24-035591-xbrl.zip	Edgar Link	pending
cdcx-20240630.htm	Edgar Link	pending
cdcx-20240630.xsd	Edgar Link	pending
cdcx-20240630_g1.jpg	Edgar Link	pending
cdxcex-311q22024.htm	Edgar Link	pending
cdxcex-312q22024.htm	Edgar Link	pending
cdxcex-321q22024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
cdcx-20240630_cal.xml	Edgar Link	unprocessable
cdcx-20240630_def.xml	Edgar Link	unprocessable
cdcx-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdcx-20240630_pre.xml	Edgar Link	unprocessable
cdcx-20240630_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXC
ChromaDex Corp. Stock $cdxc

2024 Q3 Form 10-Q Financial Statement

#000162828024035591 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC ChromaDex Corp. Stock $cdxc

2024 Q3 Form 10-Q Financial Statement

#000162828024035591 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC
ChromaDex Corp. Stock $cdxc